BiotechTube
Home/Kyowa Kirin/Nobuo Hanai
NH

Nobuo Hanai

Chairman of the Board

Kyowa Kirin

Therapeutic Areas

Rare DiseasesOncologyImmunologyNephrologyHematology

Kyowa Kirin Pipeline

DrugIndicationPhase
Mogamulizumab (Poteligeo)Cutaneous T-cell lymphomaApproved
Burosumab (Crysvita)X-linked hypophosphatemiaApproved
Evocalcet (Orkedia)Secondary hyperparathyroidismApproved
KW-6356Atopic dermatitisPhase 2
MezagitamabB-cell malignanciesPhase 1/2
KHK4083Atopic dermatitisPhase 2
Romiplostim (Nplate)ThrombocytopeniaApproved
Darbepoetin alfaAnemiaApproved

Leadership Team at Kyowa Kirin

MM
Masashi Miyamoto
President and Chief Executive Officer
TY
Takeyoshi Yamashita
Executive Vice President
WM
Wataru Murata
Chief Financial Officer
YK
Yuki Kuroda
Senior Vice President, Corporate Strategy
MK
Motohiko Kawaguchi
Senior Vice President, R&D
View full Kyowa Kirin profile